A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PART I Cautionary Note Regarding Forward-Looking Statements: You should read the following report together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document. This report contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties and reflect Ligand’s judgment as of the date of this report. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 268M | 268M | 167M | 131M | 196M | 242M |
| Net Income | 124M | 124M | -4.0M | 52M | -33M | 57M |
| EPS | $6.13 | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 |
| Free Cash Flow | 49M | 49M | 95M | 46M | 120M | 70M |
| ROIC | 8.5% | 8.5% | -0.5% | 7.4% | 0.4% | 13.0% |
| Gross Margin | 87.8% | 87.8% | 80.3% | 74.4% | 82.6% | 85.8% |
| Debt/Equity | 0.44 | 0.44 | 0.00 | 0.00 | 0.00 | 0.39 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 41M | 41M | -23M | 12M | 3.0M | 104M |
| Operating Margin | 15.3% | 15.3% | -13.5% | 9.1% | 1.5% | 43.0% |
| ROE | 12.2% | 13.5% | -0.5% | 7.4% | -5.6% | 7.0% |
| Shares Outstanding | 20M | 20M | 18M | 18M | 17M | 17M |
LIGAND PHARMACEUTICALS INC passes 4 of 9 quality checks, suggesting mixed fundamentals.
LIGAND PHARMACEUTICALS INC trades at 0.0x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range. The company's 5-year average ROIC is 5.8% with a gross margin of 82.2%. Total shareholder yield (buybacks) is 46177.1%.
LIGAND PHARMACEUTICALS INC (LGNDZ) has a current P/E ratio of 0.0, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
LIGAND PHARMACEUTICALS INC (LGNDZ) has a 5-year average return on invested capital (ROIC) of 5.8%. This is below average and may indicate limited pricing power.
LIGAND PHARMACEUTICALS INC (LGNDZ) has a market capitalization of $32K. It is classified as a small-cap stock.
LIGAND PHARMACEUTICALS INC (LGNDZ) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 46177.07%.
Based on historical P/E analysis, LIGAND PHARMACEUTICALS INC (LGNDZ) appears cheap. The current P/E of 0.0 is 100% below its historical median of 15.0.
LIGAND PHARMACEUTICALS INC (LGNDZ) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
LIGAND PHARMACEUTICALS INC (LGNDZ) reported annual revenue of $268 million in its most recent fiscal year, based on SEC EDGAR filings.
LIGAND PHARMACEUTICALS INC (LGNDZ) has a net profit margin of 46.4%. This is a strong margin indicating high profitability.
LIGAND PHARMACEUTICALS INC (LGNDZ) generated $49 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
LIGAND PHARMACEUTICALS INC (LGNDZ) has a debt-to-equity ratio of 0.44. This indicates a conservatively financed balance sheet.
LIGAND PHARMACEUTICALS INC (LGNDZ) reported earnings per share (EPS) of $6.13 in its most recent fiscal year.
LIGAND PHARMACEUTICALS INC (LGNDZ) has a return on equity (ROE) of 13.5%. This indicates moderate shareholder returns.
LIGAND PHARMACEUTICALS INC (LGNDZ) has a 5-year average gross margin of 82.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for LIGAND PHARMACEUTICALS INC (LGNDZ), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LIGAND PHARMACEUTICALS INC (LGNDZ) has a book value per share of $50.10, based on its most recent annual SEC filing.
No recent press releases.